EcoR1 Capital as of March 31, 2020
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 51 positions in its portfolio as reported in the March 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Prothena (PRTA) | 10.5 | $101M | 9.4M | 10.70 | |
| Xencor (XNCR) | 7.8 | $75M | 2.5M | 29.88 | |
| Arvinas Ord (ARVN) | 6.4 | $62M | 1.5M | 40.30 | |
| Dicerna Pharmaceuticals | 6.4 | $62M | 3.3M | 18.37 | |
| Fate Therapeutics (FATE) | 5.4 | $52M | 2.3M | 22.21 | |
| Ironwood Pharmaceuticals (IRWD) | 4.6 | $44M | 4.4M | 10.09 | |
| Anaptysbio Inc Common (ANAB) | 4.5 | $43M | 3.0M | 14.13 | |
| Neoleukin Therapeutics | 4.4 | $42M | 3.7M | 11.38 | |
| Morphic Hldg (MORF) | 4.3 | $41M | 2.8M | 14.68 | |
| Assembly Biosciences | 4.0 | $38M | 2.6M | 14.83 | |
| Kura Oncology (KURA) | 3.7 | $35M | 3.5M | 9.95 | |
| Fibrogen | 3.2 | $31M | 882k | 34.75 | |
| Innate Pharma (IPHA) | 3.1 | $30M | 4.5M | 6.68 | |
| Mirati Therapeutics | 2.9 | $28M | 358k | 76.87 | |
| Prevail Therapeutics Ord | 2.9 | $27M | 2.2M | 12.19 | |
| Puma Biotechnology (PBYI) | 2.2 | $21M | 2.5M | 8.44 | |
| Merus N V (MRUS) | 2.2 | $21M | 1.7M | 12.10 | |
| Atreca Inc Cl A (BCEL) | 1.9 | $18M | 1.1M | 16.55 | |
| Ultragenyx Pharmaceutical (RARE) | 1.7 | $17M | 371k | 44.43 | |
| Sangamo Biosciences (SGMO) | 1.5 | $15M | 2.3M | 6.37 | |
| Genmab A/s -sp (GMAB) | 1.4 | $14M | 654k | 21.19 | |
| ACADIA Pharmaceuticals (ACAD) | 1.4 | $14M | 324k | 42.25 | |
| Denali Therapeutics (DNLI) | 1.3 | $12M | 698k | 17.51 | |
| Amicus Therapeutics (FOLD) | 1.2 | $12M | 1.2M | 9.24 | |
| Selecta Biosciences | 1.2 | $11M | 4.6M | 2.41 | |
| Ionis Pharmaceuticals (IONS) | 1.0 | $9.9M | 209k | 47.28 | |
| Vir Biotechnology (VIR) | 1.0 | $9.3M | 270k | 34.27 | |
| ZIOPHARM Oncology | 1.0 | $9.2M | 3.8M | 2.45 | |
| Verastem | 0.9 | $8.6M | 3.3M | 2.64 | |
| Rts/bristol-myers Squibb Compa | 0.9 | $8.5M | 2.2M | 3.80 | |
| Cyclerion Therapeutics | 0.8 | $7.3M | 2.7M | 2.65 | |
| Chiasma | 0.6 | $5.5M | 1.5M | 3.65 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.5 | $5.1M | 350k | 14.70 | |
| Exicure | 0.4 | $4.2M | 2.8M | 1.48 | |
| Arcus Biosciences Incorporated (RCUS) | 0.4 | $4.1M | 292k | 13.88 | |
| Savara (SVRA) | 0.3 | $3.0M | 1.4M | 2.12 | |
| Lifesci Acquisition Corp unit 03/31/2025 | 0.3 | $3.0M | 300k | 10.00 | |
| Surface Oncology | 0.2 | $2.4M | 1.3M | 1.87 | |
| Aclaris Therapeutics (ACRS) | 0.2 | $2.2M | 2.1M | 1.04 | |
| Corvus Pharmaceuticals (CRVS) | 0.2 | $1.6M | 738k | 2.11 | |
| Zymeworks | 0.2 | $1.5M | 41k | 35.48 | |
| Crispr Therapeutics (CRSP) | 0.1 | $1.3M | 31k | 42.41 | |
| Meiragtx Holdings (MGTX) | 0.1 | $1.3M | 95k | 13.44 | |
| Trillium Therapeutics, Inc. Cmn | 0.1 | $1.2M | 292k | 4.04 | |
| Xoma Corp Del (XOMA) | 0.1 | $1.0M | 51k | 20.35 | |
| Regulus Therapeutics | 0.1 | $870k | 1.9M | 0.46 | |
| Blueprint Medicines (BPMC) | 0.1 | $816k | 14k | 58.51 | |
| Pieris Pharmaceuticals | 0.1 | $602k | 264k | 2.28 | |
| Five Prime Therapeutics | 0.1 | $581k | 256k | 2.27 | |
| Exelixis (EXEL) | 0.0 | $108k | 6.3k | 17.23 | |
| Cytomx Therapeutics (CTMX) | 0.0 | $8.0k | 1.1k | 7.27 |
